Gilteritinib (Xospata)
Canadian Journal of Health Technologies · 29.10.2026 · 6 (10)
DOI: 10.51731/cjht.2026.1555 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Health Technologies, online erschienen am 29.10.2026. Verfasst von CDA-AMC.
Abstract (Originalsprache)
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses gilteritinib (Xospata), 40 mg, tablet, oral. Indication: The treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation.
Zitieren
APA
CDA-AMC (2026). Gilteritinib (Xospata). Canadian Journal of Health Technologies, 6(10). https://doi.org/10.51731/cjht.2026.1555
Vancouver
CDA-AMC. Gilteritinib (Xospata). Canadian Journal of Health Technologies. 2026;6(10). doi:10.51731/cjht.2026.1555
BibTeX
@article{CDAAMC2026,
author = {CDA-AMC},
title = {Gilteritinib (Xospata)},
journal = {Canadian Journal of Health Technologies},
year = {2026},
volume = {6},
number = {10},
doi = {10.51731/cjht.2026.1555}
}
EUVIMED